Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in CYP1A1-Ren-2 transgenic rats with acutely induced hypertension

Vascular Pharmacology

Volumn 50, Issue 5-6, 2009, Pages 194-199

  Vaňourková, Zdeňka ^a   Kramer, Herbert J ^b   Erbanová, Michaela ^a   Bäcker, Angela ^b   Červenka, Luděk ^a,c   Husková, Zuzana ^a   Chábová, Věra Čertíková ^a,c   Tesař, Vladimír ^c   Dvořák, Pavel ^c   Malý, Jan ^a   Vaněčková, Ivana ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b Medical Policlinic   (Germany)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cyp1A1 Ren 2 rats; Endothelin receptors; Hypertension; Inducible

Indexed keywords

3 INDOLEMETHANOL; ANGIOTENSIN II; ATRASENTAN; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; CONTROLLED STUDY; CYP1A1 REN 2 TRANSGENIC RAT; DISEASE COURSE; DRUG SELECTIVITY; GENE; HEART VENTRICLE; HYPERTENSION; MALE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROMOTER REGION; RAT; RAT STRAIN; REN 2 GENE; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL; TRANSGENIC RAT; WEIGHT REDUCTION;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CYTOCHROME P-450 CYP1A1; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; HEART VENTRICLES; HYPERTENSION; INDOLES; KIDNEY; MALE; PYRROLIDINES; RATS; RATS, TRANSGENIC; RECEPTORS, ENDOTHELIN; RENIN; SULFONAMIDES;

EID: 61349153632     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.01.002     Document Type: Article

References (35)

1. Backer A., Bokemeyer D., and Kramer H.J. Endothelin synthesis and receptors in porcine kidney. Acta Physiol. Scand. 171 (2001) 105-112
2. Banes-Berceli A.K., Ketsawatsomkron P., Ogbi S., Patel B., Pollock D.M., and Marrero M.B. Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H1291-H1299
3. Bohlender J., Gerbaulet S., Kramer J., Gross M., Kirchengast M., and Dietz R. Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension 35 (2000) 992-997
4. Callahan M.F., Li P., Ferrario C.M., Ganten D., and Morris M. Salt-sensitive hypertension in (mREN-2)27 transgenic rats. Hypertension 27 (1996) 573-577
5. Collidge T.A., Lammie G.A., Fleming S., and Mullins J.J. The role of the renin-angiotensin system in malignant vascular injury affecting the systemic and cerebral circulations. Prog. Biophys. Mol. Biol. 84 (2004) 301-319
6. D'Angelo G., Pollock J.S., and Pollock D.M. Endogenous endothelin attenuates the pressor response to acute environmental stress via the ETA receptor. Am. J. Physiol Heart Circ. Physiol. 288 (2005) H1829-H1835
7. Dobešová Z., Kuneš J., and Zicha J. Less important role of endothelin in salt hypertension of young than adult Dahl rats. Physiol. Res. 52 (2003) 49P
8. Dvorak P., Kramer H.J., Backer A., Maly J., Kopkan L., Vaneckova I., Vernerova Z., Opocensky M., Tesar V., Bader M., Ganten D., Janda J., and Cervenka L. Blockade of endothelin receptors attenuates end-organ damage in homozygous hypertensive ren-2 transgenic rats. Kidney Blood Press Res. 27 (2004) 248-258
9. Feldstein C., and Romero C. Role of endothelins in hypertension. Am. J. Ther. 14 (2007) 147-153
10. Gerbaulet S.P., Kramer J., Bohlender J., Dietz R., and Gross C.M. Blood pressure-independent ETA and AT1 receptor blocker effects on the coronaries of rats harboring human renin and angiotensinogen genes. Kidney Blood Press Res. 28 (2005) 134-143
11. Ge Y., Bagnali A., Stricklett P.K., Strait K., Webb D.J., Kotelevtsev Y., and Kohan D.E. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am. J. Physiol. 291 (2006) F1274-1280
12. Girchev R.A., Bäcker A., Markova P.P., and Kramer H.J. Impaired response of the denervated kidney to endothelin receptor blockade in normotensive and spontaneously hypertensive rats. Kidney Int. 65 (2004) 982-989
13. Graciano M.L., Mouton C.R., Patterson M.E., Seth D.M., Mullins J.J., and Mitchell K.D. Renal vascular and tubulointerstitial inflammation and proliferation in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am. J. Physiol. Renal Physiol. 292 (2007) F1858-F1866
14. Heller J., and Hellerova S. Long-term effect on blood pressure of early brief treatment by different antihypertensive agents: a study in the Prague hypertensive rat. Kidney Blood Press Res. 21 (1998) 445-451
15. Howard L.L., Patterson M.E., Mullins J.J., and Mitchell K.D. Salt-sensitive hypertension develops after transient induction of ANG II-dependent hypertension in Cyp1a1-Ren2 transgenic rats. Am. J. Physiol. Renal Physiol. 288 (2005) F810-F815
16. Kantachuvesiri S., Fleming S., Peters J., Peters B., Brooker G., Lammie A.G., McGrath I., Kotelevtsev Y., and Mullins J.J. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J. Biol. Chem. 276 (2001) 36727-36733
17. Kramer H.J., Schwarting K., Backer A., and Meyer-Lehnert H. Renal endothelin system in obstructive jaundice: its role in impaired renal function of bile-duct ligated rats. Clin. Sci. (Lond) 92 (1997) 579-585
18. Mitchell K.D., and Mullins J.J. Enhanced tubuloglomerular feedback in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am. J. Physiol. Renal Physiol. 289 (2005) F1210-F1216
19. Mitchell K.D., Bagatell S.J., Miller C.S., Mouton C.R., Seth D.M., and Mullins J.J. Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats. J. Renin Angiotensin Aldosterone Syst. 7 (2006) 74-86
20. Moreau P., and Schiffrin E.L. Role of endothelins in animal models of hypertension: focus on cardiovascular protection. Can. J. Physiol. Pharmacol. 81 (2003) 511-521
21. Muller D.N., Mervaala E.M., Schmidt F., Park J.K., Dechend R., Genersch E., Breu V., Loffler B.M., Ganten D., Schneider W., Haller H., and Luft F.C. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 36 (2000) 282-290
22. Navar L.G., Lewis L., Hymel A., Braam B., and Mitchell K.D. Tubular fluid concentrations and kidney contents of angiotensins I and II in anesthetized rats. J. Am. Soc. Nephrol. 5 (1994) 1153-1158
23. Opay A.L., Mouton C.R., Mullins J.J., and Mitchell K.D. Cyclooxygenase-2 inhibition normalizes arterial blood pressure in CYP1A1-REN2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am. J. Physiol. Renal Physiol. 291 (2006) F612-F618
24. Opgenorth T.J., Adler A.L., Calzadilla S.V., Chiou W.J., Dayton B.D., Dixon D.B., Gehrke L.J., Hernandez L., Magnuson S.R., Marsh K.C., Novosad E.I., von Geldern T.W., Wessale J.L., Winn M., and Wu-Wong J.R. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J. Pharmacol. Exp. Ther. 276 (1996) 473-481
25. Opocensky M., Dvorak P., Maly J., Kramer H.J., Backer A., Kopkan L., Vernerova Z., Tesar V., Zima T., Bader M., Ganten D., Janda J., and Vaneckova I. Chronic endothelin receptor blockade reduces end-organ damage independently of blood pressure effects in salt-loaded heterozygous Ren-2 transgenic rats. Physiol. Res. 53 (2004) 581-593
26. Opocensky M., Kramer H.J., Backer A., Vernerova Z., Eis V., Cervenka L., Certikova V C., Tesar V., and Vaneckova I. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 48 (2006) 965-971
27. Patterson M.E., Mouton C.R., Mullins J.J., and Mitchell K.D. Interactive effects of superoxide anion and nitric oxide on blood pressure and renal hemodynamics in transgenic rats with inducible malignant hypertension. Am. J. Physiol. Renal Physiol. 289 (2005) F754-F759
28. Rothermund L., Pinto Y.M., Hocher B., Vetter R., Leggewie S., mehl P., Orzechowski H.D., Kreutz R., and Paul M. Cardiac endothelin system impairs left ventricular function in renin-dependent hypertension via decreased sarcoplasmic reticulum Ca2+ uptake. Circulation 102 (2000) 1582-1588
29. Roux S., Breu V., Ertel S.I., and Clozel M. Endothelin antagonism with bosentan: a review of potential applications. J. Mol. Med. 77 (1999) 364-376
30. Schiffrin E.L. Vascular endothelin in hypertension. Vascul. Pharmacol. 43 (2005) 19-29
31. Vaneckova I., Kramer H.J., Backer A., Vernerova Z., Opocensky M., and Cervenka L. Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension 46 (2005) 969-974 [part 2]
32. Vaneckova I., Kramer H.J., Backer A., Schejbalova S., Vernerova Z., Eis V., Opocensky M., Dvorak P., and Cervenka L. Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats. Vascul. Pharmacol. 45 (2006) 163-170
33. Vanourkova Z., Kramer H.J., Huskova Z., Vaneckova I., Opocensky M., Chabova V.C., Tesar V., Skaroupkova P., Thumova M., Dohnalova M., Mullins J.J., and Cervenka L. AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J. Hypertens. 24 (2006) 2465-2472
34. Vernerova Z., Kramer H.J., Backer A., Cervenka L., Opocensky M., Huskova Z., Vanourkova Z., Eis V., Chabova V.C., Tesar V., Maly J., and Vaneckova I. Late-onset endothelin receptor blockade in hypertensive heterozygous REN-2 transgenic rats. Vascul. Pharmacol. 48 (2008) 165-173
35. Vogel V., Bäcker A., Heller J., and Kramer H.J. The renal endothelin system in the Prague hypertensive rat, a new model of spontaneous hypertension. Clin. Sci. (Lond) 97 (1999) 91-98